|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HORMONES AND SIGNALING
Departments of 1Pathology and 2Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
Submitted 12 July 2004 ; accepted in final form 5 December 2004
Glucagon-like peptide 1 (GLP-1) is a gastrointestinal hormone secreted in response to meal ingestion by enteroendocrine L cells located predominantly in the lower small intestine and large intestine. GLP-1 inhibits the secretion and motility of the upper gut and has been suggested to play a role in the "ileal brake." In this study, we investigated the effect of recombinant GLP-1-(736) amide (rGLP-1) on lipid absorption in the small intestine in intestinal lymph duct-cannulated rats. In addition, the effects of rGLP-1 on intestinal production of apolipoprotein (apo) B and apo A-IV, two apolipoproteins closely related to lipid absorption, were evaluated. rGLP-1 was infused through the jugular vein, and lipids were infused simultaneously through a duodenal cannula. Our results showed that infusion of rGLP-1 at 20 pmol·kg1·min1 caused a dramatic and prompt decrease in lymph flow from 2.22 ± 0.15 (SE) ml/h at baseline (n = 6) to 1.24 ± 0.06 ml/h at 2 h (P < 0.001). In contrast, a significant increase in lymph flow was observed in the saline (control) group: 2.19 ± 0.20 and 3.48 ± 0.09 ml/h at baseline and at 6 h of lipid infusion, respectively (P < 0.001). rGLP-1 also inhibited intestinal triolein absorption (P < 0.05) and lymphatic apo B and apo A-IV output (P < 0.05) but did not affect cholesterol absorption. In conclusion, rGLP-1 dramatically decreases intestinal lymph flow and reduces triglyceride absorption and apo B and apo A-IV production. These findings suggest a novel role for GLP-1 in lipid absorption.
gut hormone; "ileal brake" effect; intestinal lymph duct cannulation
This article has been cited by other articles:
![]() |
W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cervera, E. Wajcberg, A. Sriwijitkamol, M. Fernandez, P. Zuo, C. Triplitt, N. Musi, R. A. DeFronzo, and E. Cersosimo Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E846 - E852. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D'Alessio, W. Lu, W. Sun, S. Zheng, Q. Yang, R. Seeley, S. C. Woods, and P. Tso Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2163 - R2169. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |